Szigeti B
Translational Psychedelic Research Program, Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco.
ArticlePsilocybin
An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.
ArticlePsychedelics
Psychedelics Trials and Outcomes-A Closer Look-Reply.
ArticlePsilocybin
A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.
ArticlePsychedelics
Measuring and appraising placebo effects in clinical trials: contemporary challenges and approaches in psychiatry.
ArticlePsychedelics
Psychedelic Therapy vs Antidepressants for the Treatment of Depression Under Equal Unblinding Conditions: A Systematic Review and Meta-Analysis.
ArticleMDMA
Too big to fail? Comparing effect sizes of MDMA assisted therapy to unmasking bias.
ArticleMDMA
MDMA-assisted psychotherapy for AUD: Bayesian analysis of WHO drinking risk level and exploratory analysis of drinking behavior and psychosocial functioning at 3 months follow-up.
ArticlePsilocybin
Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
PreprintMDMA
Unmasking bias and MDMA-assisted therapy
ArticlePsilocybin
Expectancy Effects in Psychedelic Trials.
ArticlePsilocybin
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.
ArticlePsychedelics
The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.
ArticlePsilocybin
Bayesian analysis of real-world data as evidence for drug approval: Remembering Sir Michael Rawlins.
PreprintPsilocybin
Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial
ArticlePsychedelics